TY - JOUR T1 - New antibiotics for Gram-negative pneumonia JF - European Respiratory Review JO - EUROPEAN RESPIRATORY REVIEW DO - 10.1183/16000617.0119-2022 VL - 31 IS - 166 SP - 220119 AU - Matteo Bassetti AU - Federica Magnè AU - Daniele Roberto Giacobbe AU - Lorenzo Bini AU - Antonio Vena Y1 - 2022/12/31 UR - http://err.ersjournals.com/content/31/166/220119.abstract N2 - Pneumonia is frequently encountered in clinical practice, and Gram-negative bacilli constitute a significant proportion of its aetiology, especially when it is acquired in a hospital setting. With the alarming global rise in multidrug resistance in Gram-negative bacilli, antibiotic therapy for treating patients with pneumonia is challenging and must be guided by in vitro susceptibility results. In this review, we provide an overview of antibiotics newly approved for the treatment of pneumonia caused by Gram-negative bacilli. Ceftazidime-avibactam, imipenem-relebactam and meropenem-vaborbactam have potent activity against some of the carbapenem-resistant Enterobacterales, especially Klebsiella pneumoniae carbapenemase producers. Several novel antibiotics have potent activity against multidrug-resistant Pseudomonas aeruginosa, such as ceftazidime-avibactam, ceftolozane-tazobactam, imipenem-relabactam and cefiderocol. Cefiderocol may also play an important role in the management of pneumonia caused by Acinetobacter baumannii, along with plazomicin and eravacycline.Thanks to new antibiotics, there is hope in the future regarding treatment of pneumonia caused by Gram-negative bacilli. https://bit.ly/3sl2sVw ER -